| 前收盘价格 | 14.80 |
| 收盘价格 | 14.72 |
| 成交量 | 100,789 |
| 平均成交量 (3个月) | 250,165 |
| 市值 | 1,905,624,832 |
| 预期市盈率 (P/E Forward) | 454.55 |
| 价格/销量 (P/S) | 30.52 |
| 股市价格/股市净资产 (P/B) | 3.56 |
| 52周波幅 | |
| 利润日期 | 26 Feb 2026 |
| 营业利益率 (TTM) | -633.21% |
| 稀释每股收益 (EPS TTM) | -1.24 |
| 季度收入增长率 (YOY) | -6.80% |
| 总债务/股东权益 (D/E MRQ) | 27.34% |
| 流动比率 (MRQ) | 0.960 |
| 营业现金流 (OCF TTM) | -42.54 M |
| 杠杆自由现金流 (LFCF TTM) | -13.46 M |
| 资产报酬率 (ROA TTM) | -4.85% |
| 股东权益报酬率 (ROE TTM) | -21.31% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Mesoblast Limited | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.38 |
|
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 0.06% |
| 机构持股比例 | 3.10% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Summit X, Llc | 30 Jun 2025 | 199,295 |
| Penbrook Management Llc | 31 Mar 2026 | 87,075 |
| Prosperity Wealth Management, Inc. | 31 Dec 2025 | 50,900 |
| Rialto Wealth Management, Llc | 31 Dec 2025 | 46,500 |
| Lazari Capital Management, Inc. | 31 Mar 2026 | 46,121 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合